Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple checklist help surgeons remove every last cancer cell?

NCT ID NCT07828938

Disease control Sponsor: Fondation Hôpital Saint-Joseph Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Researchers are testing whether a shared checklist used during lung cancer surgery helps surgeons achieve cleaner, more complete tumor removal. The trial enrolls adults with early-stage non-small cell lung cancer who are scheduled for surgery. Half the participating hospitals use the QualitySurg List, a digital tool that guides surgical quality checks in real time, while the other half continue with standard care. The main goal is to see whether the checklist increases the proportion of operations where no cancer cells remain at the edge of the removed tissue.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a collaborative intraoperative quality checklist called the QualitySurg List, combined with training and digital performance feedback
What this could lead to
If the checklist helps surgeons remove lung tumors more completely, it could become a standard tool in operating rooms and lead to fewer recurrences for people with early-stage lung cancer.
What could go wrong
The checklist may not change how completely tumors are removed, and any improvement in survival could take years to confirm. The study also relies on surgeons consistently using the tool, which is not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 2,400 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Mar 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Have solid NSCLC clinical stage IA-IIIA (according to the 9th edition of the TNM) and be eligible for surgical resection. * Have a respiratory function and a state of performance (ECOG) allowing the surgical procedure. * Primary intervention for NSCLC, whether isolated or included in a multimodal regimen (neoadjuvant/adjuvant). * Intervention can be performed by minimally invasive surgery (VATS, RATS) or by thoracotomy. * Have given written informed consent. Exclusion Criteria: * History of cancer less than five years old excluding non-melanocytic skin cancer prior to enrollment * Pure ground glass opacities regardless of tumor size * iterative re-interventions of the same stay (keep only the first planned intervention for the main analysis) * History of HIV infection, allogeneic stem cell or solid organ transplant * History of any hematological disease that is not considered to be in complete remission * Patients under guardianship or conservatorship * Patients deprived of their liberty or under judicial protection * Pregnant women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer (non-small cell) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer (non-small cell)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    20 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Avicennes

    Bobigny, France

  • Bichat Claude-Bernard

    Paris, France

  • CHU Angers

    Angers, France

  • CHU Bordeaux

    Bordeaux, France

  • CHU Dijon

    Dijon, France

  • CHU Lille

    Lille, France

  • CHU Nantes

    Nantes, France

  • CHU Poitiers

    Poitiers, France

  • CHU Rouen

    Rouen, France

  • CHU Strasbourg

    Strasbourg, France

  • CHU Toulouse

    Toulouse, France

  • CHU Tours

    Tours, France

  • CHU de Rennes

    Rennes, France

  • CLCC Jean Perrin

    Clermont-Ferrand, France

  • Chu Lyon

    Lyon, France

  • HEGP

    Paris, France

  • Hôpital Foch

    Suresnes, France

  • Hôpital Marie Lannelongue

    Le Plessis-Robinson, 92350, France

  • Hôpital Nord

    Marseille, France

  • Hôpital Tenon

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.